A jury found McKesson and Cencora liable for $266 million in damages to the city of Baltimore for fueling the opioid crisis.

Susman Godfrey partner Bill Carmody said the $266 million “verdict was an important step toward helping Baltimore recover so ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

McKesson Corporation's ( NYSE:MCK ) stock was strong despite it releasing a soft earnings report last week. Our... The city ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

McKesson (MCK) and Cencora (COR) ordered by a jury in Baltimore to pay $266M in damages to the city for their role in causing ...

A Baltimore jury found two drug distributors liable for contributing to the city's ongoing opioid crisis. The decision came ...